{"id":53342,"date":"2026-09-14T14:02:28","date_gmt":"2026-09-14T14:02:28","guid":{"rendered":"https:\/\/volity.io\/blog\/scholar-rock-fda-approval-2\/"},"modified":"2026-09-15T07:30:57","modified_gmt":"2026-09-15T07:30:57","slug":"scholar-rock-fda-approval","status":"publish","type":"post","link":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/","title":{"rendered":"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae"},"content":{"rendered":"<h2>La aprobaci\u00f3n de un f\u00e1rmaco biotecnol\u00f3gico choca con el repliegue de los chips mientras Wall Street se vuelve cauteloso<\/h2>\n\n<p>Wall Street comenz\u00f3 el lunes 14 de septiembre con un \u00e1nimo reservado. Los operadores recortaron posiciones saturadas en chips mientras examinaban nuevos catalizadores corporativos.<\/p>\n\n<p>Los semiconductores marcaron pronto el tono defensivo. Sin embargo, la biotecnolog\u00eda ofreci\u00f3 un tipo de oportunidad muy distinto.<\/p>\n\n<p>Scholar Rock se convirti\u00f3 en el valor m\u00e1s claro de la ma\u00f1ana impulsado por acontecimientos concretos. La FDA aprob\u00f3 ISEMBYLD para pacientes con atrofia muscular espinal de dos a\u00f1os o m\u00e1s.<\/p>\n\n<p>El tratamiento se dirige a pacientes que ya reciben terapias dirigidas a SMN2, como nusinersen o risdiplam. Por tanto, la aprobaci\u00f3n da a Scholar Rock su primer producto comercializado.<\/p>\n\n<p>La direcci\u00f3n program\u00f3 una llamada sobre la aprobaci\u00f3n para las 8:00 a. m., hora del Este. Los inversores quer\u00edan detalles sobre la ficha t\u00e9cnica, el calendario de lanzamiento, el reembolso y la infraestructura comercial.<\/p>\n\n<p>ISEMBYLD tambi\u00e9n conlleva un bono de revisi\u00f3n prioritaria. Ese activo podr\u00eda tener un valor significativo, ya sea mediante su venta o para el desarrollo futuro de f\u00e1rmacos.<\/p>\n\n<p>Truist elev\u00f3 su precio objetivo para Scholar Rock tras la decisi\u00f3n. La firma se\u00f1al\u00f3 un recorrido m\u00e1s largo en el mercado de la AME.<\/p>\n\n<p>Aun as\u00ed, SRRK afronta ahora una fase m\u00e1s exigente. El riesgo de aprobaci\u00f3n ha quedado atr\u00e1s, pero ha llegado el riesgo de ejecuci\u00f3n comercial.<\/p>\n\n<p>Los operadores estar\u00e1n atentos a si la direcci\u00f3n cuantifica la demanda inicial. Tambi\u00e9n buscar\u00e1n orientaciones sobre el contacto con especialistas y la cobertura de las aseguradoras.<\/p>\n\n<h3>Intel cede terreno<\/h3>\n\n<p>Las acciones de Intel cayeron m\u00e1s de un 6 % en las primeras operaciones. El movimiento prolong\u00f3 un reciente retroceso del sector de semiconductores.<\/p>\n\n<p>Esa debilidad lleg\u00f3 tras una racha extraordinaria. INTC hab\u00eda ganado alrededor de un 188 % en lo que va de a\u00f1o antes de las ventas del lunes.<\/p>\n\n<p>Unas ganancias as\u00ed dejan poco margen para la decepci\u00f3n. En consecuencia, las preocupaciones sobre la demanda de chips y los m\u00e1rgenes han pesado m\u00e1s.<\/p>\n\n<p>Los comentarios recientes de los analistas del lado vendedor tambi\u00e9n han enfriado el sentimiento. Los analistas han cuestionado la trayectoria de beneficios a corto plazo de Intel y la visibilidad de su demanda.<\/p>\n\n<p>Las acciones se han vuelto muy sensibles a los rendimientos y a los flujos sectoriales. Los acontecimientos propios de la compa\u00f1\u00eda compiten ahora con el apetito general por el riesgo.<\/p>\n\n<p>El iShares Semiconductor ETF se mantuvo por debajo de sus m\u00e1ximos de finales del verano. Mientras tanto, los valores de chips han ca\u00eddo recientemente m\u00e1s r\u00e1pido que el sector tecnol\u00f3gico en general.<\/p>\n\n<p>Esa diferencia importa a los operadores. Intel se comporta menos como una historia de recuperaci\u00f3n y m\u00e1s como una posici\u00f3n saturada y sensible a los tipos de inter\u00e9s.<\/p>\n\n<ul>\n  <li><b>INTC:<\/b> Baja m\u00e1s de un 6 % a primera hora del lunes tras una subida de alrededor del 188 % en lo que va de a\u00f1o.<\/li>\n  <li><b>SRRK:<\/b> La aprobaci\u00f3n de la FDA, el lanzamiento del producto y la llamada de la direcci\u00f3n crean un catalizador activo.<\/li>\n  <li><b>CHTR:<\/b> Los recortes de precio objetivo refuerzan las dudas sobre el crecimiento de la banda ancha y la competencia.<\/li>\n  <li><b>SPY y QQQ:<\/b> Siguen siendo instrumentos clave para expresar cautela antes de la reuni\u00f3n de la Reserva Federal (Fed).<\/li>\n<\/ul>\n\n<h3>El software encuentra un terreno m\u00e1s firme<\/h3>\n\n<p>La subida de los rendimientos del Tesoro de EE. UU. ha favorecido una rotaci\u00f3n hacia la calidad percibida. Sin embargo, los inversores no han abandonado del todo la tecnolog\u00eda.<\/p>\n\n<p>Las grandes plataformas de software han resistido mejor que los valores especulativos de hardware. ServiceNow se ha beneficiado de esa fortaleza relativa.<\/p>\n\n<p>Las acciones de ciberseguridad tambi\u00e9n han atra\u00eddo el inter\u00e9s institucional. CrowdStrike y Palo Alto Networks encajan con la preferencia por los ingresos recurrentes y la demanda visible.<\/p>\n\n<p>Los inversores tratan cada vez m\u00e1s a esos grupos como coberturas seguras frente a la IA. En cambio, los valores de hardware afrontan una mayor sensibilidad a la valoraci\u00f3n y a la cadena de suministro.<\/p>\n\n<p>No se trata de una huida generalizada del crecimiento. M\u00e1s bien, es un movimiento hacia negocios con flujo de caja consolidado e ingresos por suscripci\u00f3n.<\/p>\n\n<p>Oracle, Nvidia y Micron siguen siendo bar\u00f3metros importantes del mercado. Sin embargo, cada uno cotiza ahora en un entorno menos indulgente para los activos de larga duraci\u00f3n.<\/p>\n\n<p>Tesla tambi\u00e9n sigue siendo un indicador \u00fatil del apetito especulativo. La actividad en opciones sugiere que el posicionamiento a corto plazo todav\u00eda impulsa gran parte de su negociaci\u00f3n.<\/p>\n\n<h3>Charter sigue bajo presi\u00f3n<\/h3>\n\n<p>Charter Communications sigui\u00f3 en el radar de los operadores tras otra ronda de comentarios prudentes de los analistas. El grupo de cable afronta expectativas cada vez peores sobre el crecimiento de la banda ancha.<\/p>\n\n<p>Bernstein SocGen recort\u00f3 su precio objetivo para Charter a $150 desde $170 durante el verano. Mantuvo una recomendaci\u00f3n de rendimiento en l\u00ednea con el mercado.<\/p>\n\n<p>La firma cit\u00f3 la competencia y unas perspectivas m\u00e1s dif\u00edciles para la banda ancha. Desde entonces, notas m\u00e1s recientes han apuntado a posibles ca\u00eddas hasta poco m\u00e1s de $100.<\/p>\n\n<p>Esos objetivos no representan el consenso. No obstante, su direcci\u00f3n refleja un reajuste m\u00e1s amplio de las expectativas del sector del cable.<\/p>\n\n<p>Los inversores valoraban antes a Charter como un valor de crecimiento compuesto, duradero y estructural. Ahora, el mercado ve cada vez m\u00e1s un operador de crecimiento m\u00e1s lento bajo presi\u00f3n competitiva.<\/p>\n\n<p>Ese cambio puede ser dif\u00edcil de revertir. Por tanto, cualquier recuperaci\u00f3n probablemente necesite datos de abonados que muestren estabilizaci\u00f3n, y no simplemente m\u00faltiplos de valoraci\u00f3n m\u00e1s baratos.<\/p>\n\n<h3>Las acciones de valor esperan se\u00f1ales m\u00e1s claras<\/h3>\n\n<p>En otros \u00e1mbitos, las estrategias de dividendos y de valor siguieron coci\u00e9ndose a fuego lento bajo los titulares tecnol\u00f3gicos. Thor Industries ilustra esa tensi\u00f3n.<\/p>\n\n<p>Su rentabilidad por dividendo puede atraer a los inversores que buscan rentas. Sin embargo, unas expectativas de beneficios m\u00e1s d\u00e9biles mantienen la acci\u00f3n ligada al ciclo industrial.<\/p>\n\n<p>Freeport-McMoRan, Delta Air Lines y Kimberly-Clark tambi\u00e9n siguen en listas de seguimiento activas. Cada una depende de variables macroecon\u00f3micas distintas.<\/p>\n\n<p>Freeport necesita el apoyo de la demanda de cobre. Delta necesita un gasto en viajes resistente, mientras que Kimberly-Clark necesita una demanda de consumo y unos costes de insumos m\u00e1s estables.<\/p>\n\n<p>Por ahora, pocos inversores parecen dispuestos a asumir compromisos desmesurados. La reuni\u00f3n de la Reserva Federal y los precios de la energ\u00eda podr\u00edan cambiar ese c\u00e1lculo.<\/p>\n\n<h3>Lo que vigilan los operadores<\/h3>\n\n<ol>\n  <li>Los planes de lanzamiento de Scholar Rock, los comentarios sobre el reembolso y cualquier indicador temprano de demanda de ISEMBYLD.<\/li>\n  <li>Si Intel puede aguantar tras su fuerte retroceso desde los m\u00e1ximos de este a\u00f1o.<\/li>\n  <li>Nuevos recortes de precio objetivo o advertencias sobre abonados que afecten a Charter.<\/li>\n  <li>Los rendimientos del Tesoro de EE. UU., que siguen marcando el rumbo de las acciones de crecimiento caras.<\/li>\n  <li>Las expectativas sobre la Fed, que se expresan r\u00e1pidamente a trav\u00e9s de SPY, QQQ y las principales opciones tecnol\u00f3gicas.<\/li>\n<\/ol>\n\n<p>La sesi\u00f3n del lunes ofreci\u00f3 una l\u00ednea divisoria sencilla. Los catalizadores reales y con fecha concentraron la mayor atenci\u00f3n.<\/p>\n\n<p>Scholar Rock ten\u00eda una aprobaci\u00f3n y una llamada. Intel registr\u00f3 una recogida de beneficios visible, mientras que Charter soportaba una nueva presi\u00f3n por rebajas de recomendaci\u00f3n.<\/p>\n\n<p>En cambio, las narrativas de largo plazo sobre la IA parec\u00edan menos operables. Los operadores mostraron m\u00e1s inter\u00e9s en lo que podr\u00eda alterar las estimaciones esta semana.<\/p>\n\n<p>En este mercado, el momento importa tanto como la convicci\u00f3n. Un catalizador validado puede mover r\u00e1pidamente el precio de una acci\u00f3n, mientras que un tema popular puede desvanecerse igual de r\u00e1pido.<\/p>\n\n\n<h2 class=\"wp-block-heading volity-related-coverage\">Art\u00edculos relacionados en Volity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/volity.io\/es\/acciones\/what-is-a-pe-ratio\/\">Qu\u00e9 es una ratio P\/E y c\u00f3mo usarla<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/es\/acciones\/fundamental-analysis-stock-trading\/\">An\u00e1lisis fundamental en trading de acciones: una definici\u00f3n pr\u00e1ctica<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/es\/acciones\/growth-investing-vs-value-investing\/\">Inversi\u00f3n growth vs inversi\u00f3n value: \u00bfqu\u00e9 estilo encaja contigo?<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/es\/acciones\/fractional-shares-explained\/\">Acciones fraccionadas explicadas: c\u00f3mo empezar a invertir con $50<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/es\/acciones\/how-to-start-stock-trading\/\">C\u00f3mo empezar el trading de acciones: una gu\u00eda para principiantes 2026<\/a><\/li>\n<li><a href=\"https:\/\/volity.io\/es\/acciones\/dividend-investing-for-beginners\/\">Inversi\u00f3n en dividendos para principiantes: c\u00f3mo empezar<\/a><\/li>\n<\/ul>\n\n\n<script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae\",\"datePublished\":\"2026-09-14T14:02:28+00:00\",\"dateModified\":\"2026-09-14T14:02:28+00:00\",\"author\":{\"@type\":\"Person\",\"name\":\"Alexander Bennett\",\"url\":\"https:\/\/volity.io\/\"},\"publisher\":{\"@type\":\"Organization\",\"name\":\"Volity\",\"url\":\"https:\/\/volity.io\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/logo.webp\",\"width\":512,\"height\":512}},\"image\":\"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/\"},\"articleSection\":\"News\",\"inLanguage\":\"es\"}<\/script>\n","protected":false},"excerpt":{"rendered":"<p>La aprobaci\u00f3n de un f\u00e1rmaco biotecnol\u00f3gico choca con el repliegue de los chips mientras Wall Street se vuelve cauteloso Wall Street comenz\u00f3 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":53335,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"custom_schema":"","footnotes":""},"categories":[223],"tags":[],"class_list":["post-53342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae | Volity<\/title>\n<meta name=\"description\" content=\"La FDA aprob\u00f3 ISEMBYLD de Scholar Rock para la atrofia muscular espinal y pone el foco en SRRK mientras Intel retrocede y Wall Street se vuelve cautelosa.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae\" \/>\n<meta property=\"og:description\" content=\"La FDA aprob\u00f3 ISEMBYLD de Scholar Rock para la atrofia muscular espinal y pone el foco en SRRK mientras Intel retrocede y Wall Street se vuelve cautelosa.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"Volity\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61570055360264\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-14T14:02:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-15T07:30:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"669\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Alexander Bennett\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@VolityBeat\" \/>\n<meta name=\"twitter:site\" content=\"@VolityBeat\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexander Bennett\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/\"},\"author\":{\"name\":\"Alexander Bennett\",\"@id\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/#person\"},\"headline\":\"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae\",\"datePublished\":\"2026-09-14T14:02:28+00:00\",\"dateModified\":\"2026-09-15T07:30:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/\"},\"wordCount\":1431,\"publisher\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ScholarRockApproval.webp\",\"articleSection\":[\"News\"],\"inLanguage\":\"es\",\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/\",\"url\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/\",\"name\":\"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae | Volity\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ScholarRockApproval.webp\",\"datePublished\":\"2026-09-14T14:02:28+00:00\",\"dateModified\":\"2026-09-15T07:30:57+00:00\",\"description\":\"La FDA aprob\u00f3 ISEMBYLD de Scholar Rock para la atrofia muscular espinal y pone el foco en SRRK mientras Intel retrocede y Wall Street se vuelve cautelosa.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/\"]}],\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\"h1\",\".entry-content > p:first-of-type\",\".entry-content h2\",\".faq-question\",\"[data-volity-takeaways]\"]}},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ScholarRockApproval.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ScholarRockApproval.webp\",\"width\":1200,\"height\":669,\"caption\":\"Scholar Rock FDA Approval Sends SRRK Into Focus as Intel Falls\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/noticias\\\/scholar-rock-fda-approval\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/volity.io\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/volity.io\\\/es\\\/\",\"name\":\"Volity - Effortless, Affordable & Transparent Access To Financial Markets\",\"description\":\"Donde cada volumen encuentra agilidad\",\"publisher\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/#organization\"},\"alternateName\":\"Volity Empowers Financial Inclusion\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/volity.io\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/#organization\",\"name\":\"Volity\",\"alternateName\":[\"VLT\",\"Volity Group\"],\"url\":\"https:\\\/\\\/volity.io\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/White-BG.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/White-BG.webp\",\"width\":1920,\"height\":1357,\"caption\":\"VOLITY\"},\"image\":{\"@id\":\"https:\\\/\\\/volity.io\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61570055360264\",\"https:\\\/\\\/x.com\\\/VolityBeat\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/volitygroup\",\"https:\\\/\\\/www.youtube.com\\\/@VolityYoutube\",\"https:\\\/\\\/www.tiktok.com\\\/@hellovolity\",\"https:\\\/\\\/t.me\\\/volitybeat\",\"https:\\\/\\\/www.trustpilot.com\\\/review\\\/volity.io\"],\"foundingDate\":\"2024\",\"legalName\":\"Volity Capital L.L.C-FZ\",\"address\":{\"@type\":\"PostalAddress\",\"addressCountry\":\"CY\",\"addressLocality\":\"Limassol\",\"streetAddress\":\"67 Spyrou Kyprianou Avenue, Kyriakides Business Center, 2nd Floor\",\"postalCode\":\"4003\"},\"contactPoint\":[{\"@type\":\"ContactPoint\",\"contactType\":\"customer support\",\"email\":\"h<!--email_off-->ello@volity.io<!--/email_off-->\",\"availableLanguage\":[\"English\",\"German\",\"French\",\"Spanish\"],\"areaServed\":[\"EU\",\"GB\",\"Worldwide\"]}],\"knowsAbout\":[\"Forex trading\",\"Contract for difference (CFD) trading\",\"Cryptocurrency trading\",\"Gold and commodities trading\",\"Stock trading\",\"Indices trading\",\"Multi-asset investment platforms\",\"Risk management\"],\"subOrganization\":[{\"@type\":\"Organization\",\"name\":\"Volity Trade Ltd\",\"identifier\":\"Saint Lucia 2024-00059\",\"description\":\"Introducing broker for UBK Markets Ltd\"},{\"@type\":\"Organization\",\"name\":\"Volity Invest Ltd\",\"identifier\":\"Cyprus HE 452984\",\"description\":\"Payment agent\"},{\"@type\":\"Organization\",\"name\":\"Volity Capital L.L.C-FZ\",\"identifier\":\"Dubai trademark 2423068\"}],\"description\":\"Providing easy-to-use, affordable and secure access to financial products with personalised experience, local market understanding, and unrivalled customer service.\",\"email\":\"h<!--email_off-->ello@volity.io<!--/email_off-->\",\"memberOf\":{\"@type\":\"Organization\",\"name\":\"CySEC, Cyprus Securities and Exchange Commission\",\"url\":\"https:\\\/\\\/www.cysec.gov.cy\\\/\",\"description\":\"Volity introduces clients to UBK Markets Ltd, a Cyprus Investment Firm authorised by CySEC under licence 186\\\/12.\"},\"hasCredential\":{\"@type\":\"EducationalOccupationalCredential\",\"name\":\"CySEC CIF licence (via UBK Markets Ltd)\",\"credentialCategory\":\"Regulatory authorisation\",\"recognizedBy\":{\"@type\":\"Organization\",\"name\":\"CySEC\",\"url\":\"https:\\\/\\\/www.cysec.gov.cy\\\/\"},\"identifier\":\"186\\\/12\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/#person\",\"name\":\"Alexander Bennett\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"url\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"contentUrl\":\"https:\\\/\\\/volity.io\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/A.Bennett-1.webp\",\"caption\":\"Alexander Bennett\"},\"description\":\"Alexander Bennett has spent over a decade reading markets, from institutional research desks to retail trading floors, and writes Volity's coverage of forex, crypto, commodities, and platforms. His work has been featured on DailyForex and TradingBeasts. His writing cuts through hype. The goal isn't moonshots; it's the disciplined edge that survives drawdowns. More on Alexander's background and approach: https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\",\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/alexanderbennettfm\\\/\",\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\"],\"jobTitle\":\"Financial Analyst & Trading Strategy Expert\",\"givenName\":\"Alexander\",\"familyName\":\"Bennett\",\"url\":\"https:\\\/\\\/volity.io\\\/alexander-bennett\\\/\",\"worksFor\":{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/volity.io\\\/#organization\",\"name\":\"Volity\"},\"knowsAbout\":[\"Forex trading\",\"Cryptocurrency markets\",\"Technical analysis\",\"Risk management\",\"CFD trading\",\"Commodities trading\",\"Trading strategy\",\"TradingView charting\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae | Volity","description":"La FDA aprob\u00f3 ISEMBYLD de Scholar Rock para la atrofia muscular espinal y pone el foco en SRRK mientras Intel retrocede y Wall Street se vuelve cautelosa.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/","og_locale":"es_ES","og_type":"article","og_title":"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae","og_description":"La FDA aprob\u00f3 ISEMBYLD de Scholar Rock para la atrofia muscular espinal y pone el foco en SRRK mientras Intel retrocede y Wall Street se vuelve cautelosa.","og_url":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/","og_site_name":"Volity","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61570055360264","article_published_time":"2026-09-14T14:02:28+00:00","article_modified_time":"2026-09-15T07:30:57+00:00","og_image":[{"width":1200,"height":669,"url":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","type":"image\/webp"}],"author":"Alexander Bennett","twitter_card":"summary_large_image","twitter_creator":"@VolityBeat","twitter_site":"@VolityBeat","twitter_misc":{"Escrito por":"Alexander Bennett","Tiempo de lectura":"7 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/#article","isPartOf":{"@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/"},"author":{"name":"Alexander Bennett","@id":"https:\/\/volity.io\/alexander-bennett\/#person"},"headline":"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae","datePublished":"2026-09-14T14:02:28+00:00","dateModified":"2026-09-15T07:30:57+00:00","mainEntityOfPage":{"@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/"},"wordCount":1431,"publisher":{"@id":"https:\/\/volity.io\/es\/#organization"},"image":{"@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","articleSection":["News"],"inLanguage":"es","speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}},{"@type":"WebPage","@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/","url":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/","name":"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae | Volity","isPartOf":{"@id":"https:\/\/volity.io\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/#primaryimage"},"image":{"@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","datePublished":"2026-09-14T14:02:28+00:00","dateModified":"2026-09-15T07:30:57+00:00","description":"La FDA aprob\u00f3 ISEMBYLD de Scholar Rock para la atrofia muscular espinal y pone el foco en SRRK mientras Intel retrocede y Wall Street se vuelve cautelosa.","breadcrumb":{"@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/"]}],"speakable":{"@type":"SpeakableSpecification","cssSelector":["h1",".entry-content > p:first-of-type",".entry-content h2",".faq-question","[data-volity-takeaways]"]}},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/#primaryimage","url":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/09\/ScholarRockApproval.webp","width":1200,"height":669,"caption":"Scholar Rock FDA Approval Sends SRRK Into Focus as Intel Falls"},{"@type":"BreadcrumbList","@id":"https:\/\/volity.io\/es\/noticias\/scholar-rock-fda-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/volity.io\/es\/"},{"@type":"ListItem","position":2,"name":"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae"}]},{"@type":"WebSite","@id":"https:\/\/volity.io\/es\/#website","url":"https:\/\/volity.io\/es\/","name":"Volity - Effortless, Affordable & Transparent Access To Financial Markets","description":"Donde cada volumen encuentra agilidad","publisher":{"@id":"https:\/\/volity.io\/es\/#organization"},"alternateName":"Volity Empowers Financial Inclusion","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/volity.io\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/volity.io\/es\/#organization","name":"Volity","alternateName":["VLT","Volity Group"],"url":"https:\/\/volity.io\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/volity.io\/es\/#\/schema\/logo\/image\/","url":"https:\/\/volity.io\/wp-content\/uploads\/2024\/08\/White-BG.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2024\/08\/White-BG.webp","width":1920,"height":1357,"caption":"VOLITY"},"image":{"@id":"https:\/\/volity.io\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61570055360264","https:\/\/x.com\/VolityBeat","https:\/\/www.linkedin.com\/company\/volitygroup","https:\/\/www.youtube.com\/@VolityYoutube","https:\/\/www.tiktok.com\/@hellovolity","https:\/\/t.me\/volitybeat","https:\/\/www.trustpilot.com\/review\/volity.io"],"foundingDate":"2024","legalName":"Volity Capital L.L.C-FZ","address":{"@type":"PostalAddress","addressCountry":"CY","addressLocality":"Limassol","streetAddress":"67 Spyrou Kyprianou Avenue, Kyriakides Business Center, 2nd Floor","postalCode":"4003"},"contactPoint":[{"@type":"ContactPoint","contactType":"customer support","email":"h<!--email_off-->ello@volity.io<!--/email_off-->","availableLanguage":["English","German","French","Spanish"],"areaServed":["EU","GB","Worldwide"]}],"knowsAbout":["Forex trading","Contract for difference (CFD) trading","Cryptocurrency trading","Gold and commodities trading","Stock trading","Indices trading","Multi-asset investment platforms","Risk management"],"subOrganization":[{"@type":"Organization","name":"Volity Trade Ltd","identifier":"Saint Lucia 2024-00059","description":"Introducing broker for UBK Markets Ltd"},{"@type":"Organization","name":"Volity Invest Ltd","identifier":"Cyprus HE 452984","description":"Payment agent"},{"@type":"Organization","name":"Volity Capital L.L.C-FZ","identifier":"Dubai trademark 2423068"}],"description":"Providing easy-to-use, affordable and secure access to financial products with personalised experience, local market understanding, and unrivalled customer service.","email":"h<!--email_off-->ello@volity.io<!--/email_off-->","memberOf":{"@type":"Organization","name":"CySEC, Cyprus Securities and Exchange Commission","url":"https:\/\/www.cysec.gov.cy\/","description":"Volity introduces clients to UBK Markets Ltd, a Cyprus Investment Firm authorised by CySEC under licence 186\/12."},"hasCredential":{"@type":"EducationalOccupationalCredential","name":"CySEC CIF licence (via UBK Markets Ltd)","credentialCategory":"Regulatory authorisation","recognizedBy":{"@type":"Organization","name":"CySEC","url":"https:\/\/www.cysec.gov.cy\/"},"identifier":"186\/12"}},{"@type":"Person","@id":"https:\/\/volity.io\/alexander-bennett\/#person","name":"Alexander Bennett","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","url":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","contentUrl":"https:\/\/volity.io\/wp-content\/uploads\/2026\/03\/A.Bennett-1.webp","caption":"Alexander Bennett"},"description":"Alexander Bennett has spent over a decade reading markets, from institutional research desks to retail trading floors, and writes Volity's coverage of forex, crypto, commodities, and platforms. His work has been featured on DailyForex and TradingBeasts. His writing cuts through hype. The goal isn't moonshots; it's the disciplined edge that survives drawdowns. More on Alexander's background and approach: https:\/\/volity.io\/alexander-bennett\/","sameAs":["https:\/\/www.linkedin.com\/in\/alexanderbennettfm\/","https:\/\/volity.io\/alexander-bennett\/"],"jobTitle":"Financial Analyst & Trading Strategy Expert","givenName":"Alexander","familyName":"Bennett","url":"https:\/\/volity.io\/alexander-bennett\/","worksFor":{"@type":"Organization","@id":"https:\/\/volity.io\/#organization","name":"Volity"},"knowsAbout":["Forex trading","Cryptocurrency markets","Technical analysis","Risk management","CFD trading","Commodities trading","Trading strategy","TradingView charting"]}]}},"yoast_meta":{"yoast_wpseo_title":"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae %%sep%% %%sitename%%","yoast_wpseo_metadesc":"La FDA aprob\u00f3 ISEMBYLD de Scholar Rock para la atrofia muscular espinal y pone el foco en SRRK mientras Intel retrocede y Wall Street se vuelve cautelosa.","yoast_wpseo_focuskw":"scholar rock aprobaci\u00f3n fda srrk","yoast_wpseo_opengraph-title":"","yoast_wpseo_opengraph-description":"","yoast_wpseo_twitter-title":"","yoast_wpseo_twitter-description":""},"yoast_title":"La aprobaci\u00f3n de la FDA pone el foco en Scholar Rock (SRRK) mientras Intel cae %%sep%% %%sitename%%","yoast_metadesc":"La FDA aprob\u00f3 ISEMBYLD de Scholar Rock para la atrofia muscular espinal y pone el foco en SRRK mientras Intel retrocede y Wall Street se vuelve cautelosa.","_links":{"self":[{"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/posts\/53342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/comments?post=53342"}],"version-history":[{"count":0,"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/posts\/53342\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/media\/53335"}],"wp:attachment":[{"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/media?parent=53342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/categories?post=53342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/volity.io\/es\/wp-json\/wp\/v2\/tags?post=53342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}